The ImmunoVerse™

The ImmunoVerse™ is a monthly podcast exploring the past, present and future of immunotherapy and delving into every intricacy of the body's immune system. Hosted by Moffitt Cancer Center President and CEO, Dr. Patrick Hwu , each episode highlights the trailblazing visionaries who are pushing boundaries in this ever-evolving, world-changing field.

The ImmunoVerse™ is a health podcast hosted by Moffitt Cancer Center, with 20 episodes on record and a Required Pod Score of 80.

Moffitt Cancer Center hosts The ImmunoVerse™, a health show with 20 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  The ImmunoVerse™

  Completing the Cancer Immunity Cycle, ft. Dr. Ira Mellman

  Sep 17, 202625 min

  Dr. Patrick Hwu sits down with Dr. Ira Mellman, president of research at the Parker Institute for Cancer Immunotherapy, to explore the science behind immune activation and its application to cancer treatment. Together, they discuss Dr. Mellman’s pioneering work on dendritic cells and endosomes, the cancer-immunity cycle, and why checkpoint inhibitors only work when enough tumor-fighting T cells are already present. Dr. Mellman explains how personalized cancer vaccines could generate stronger immune responses, the challenges of making these treatments scalable, and why ambitious science and thoughtful mentorship are essential to advancing immunotherapy. What You’ll Learn From Dr. Ira Mellman How endosomes and dendritic cells shape antigen presentation and T-cell activation The role of the cancer-immunity cycle in understanding immune responses and treatment resistance Why rate-limiting steps in the cancer-immunity cycle matter for immunotherapy How cancer vaccines can generate antigen-specific T-cell responses The importance of innate immune signals in developing effective cancer vaccines Emerging approaches to personalized cancer vaccines and their scalability

  ListenShow Notes
• 

  The ImmunoVerse™

  Reengineering CAR T Cells for Solid Tumors, ft. Dr. Yvonne Chen

  Aug 20, 202628 min

  Dr. Patrick Hwu speaks with Dr. Yvonne Chen about how engineering is shaping the future of CAR T-cell therapy. They discuss logic-gated CAR T-cells, strategies to prevent tumor escape, and new approaches for treating solid tumors such as glioblastoma. Dr. Chen also shares how her engineering background influences both her research and mentorship style.

  ListenShow Notes
• 

  The ImmunoVerse™

  T-Cell Exhaustion: From Biological Adaptation to Cancer Therapy, ft. Dr. John Wherry

  Jul 23, 202624 min

  Dr. Patrick Hwu speaks with Dr. John Wherry, a world-renowned expert in T-cell biology and director of the Institute for Immunology and Immune Health at the University of Pennsylvania. Dr. Wherry reflects on his early interest in science and explains how chronic stimulation can cause T cells to become exhausted, limiting their ability to fight cancer and persistent infections. The conversation explores how immunotherapies such as PD-1 blockade can reinvigorate exhausted T cells, why some patients do not respond, and how the tumor microenvironment and epigenetic scarring shape immune function. Dr. Wherry also discusses the future of personalized immunotherapy, the importance of mentorship and collaboration, and how music inspires creativity in both science and life. What You’ll Learn with Dr. John Wherry Why T cells "burn out" and what that means for cancer treatment How today's most successful immunotherapies work to release the immune system's brakes Why immunotherapy doesn't work for every patient—and how researchers are working to change that How a tumor's "neighborhood" can influence the immune system's ability to fight cancer The promise of reprogramming exhausted immune cells to create more effective cancer treatments Where cancer immunotherapy is headed next, from personalized approaches to new vaccine strategies

  ListenShow Notes
• 

  The ImmunoVerse™

  Reprogramming Macrophages: From Tissue Repair to Cancer Immunotherapy, ft. Dr. Miriam Merad

  Jun 25, 202622 min

  Dr. Patrick Hwu speaks with Dr. Miriam Merad, a leading physician-scientist in dendritic cell and macrophage biology at the Icahn School of Medicine at Mount Sinai. Dr. Merad reflects on her path from medicine to immunology and discusses how tissue-resident macrophages help maintain organ health but can also be fooled by tumors into supporting cancer growth. The conversation explores ways to reprogram macrophages for cancer treatment, the link between aging, inflammation and cancer risk, and the importance of multidisciplinary collaboration, data science and sustained research investment in advancing future cures. What You’ll Learn with Dr. Miriam Merad The role of macrophages in cancer, inflammation and tissue repair Why cancer can exploit the body's natural wound-healing processes New immunotherapy approaches that target and reprogram macrophages The connection between aging, chronic inflammation and cancer risk The future of macrophage-based cancer treatments Mentorship strategies for developing the next generation of immunology leaders

  ListenShow Notes
• 

  The ImmunoVerse™

  Inside the Microbiome: Fiber, Gut Health and Immunotherapy, ft. Dr. Jennifer Wargo

  May 21, 202625 minS0

  <p>Dr. Patrick Hwu sits down with Dr. Jennifer Wargo, Professor of Surgical Oncology and Genomic Medicine, leader of the platform for innovative microbiome and translational research at The University of Texas MD Anderson Cancer Center, to discuss how the tumor microbiome and host factors shape cancer development and response to immunotherapy.</p> <p>Together, they explore the growing evidence that cancer is influenced not only by tumor genetics and the immune system but also by the communities of bacteria that live within and around tumors. Dr. Wargo explains how differences in the gut and tumor microbiome can affect immune...

  ListenShow Notes

Recent guests on The ImmunoVerse™. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.